Experimental drug K0706 tested for lewy body dementia
NCT ID NCT03996460
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a drug called K0706 is safe and tolerable for people with Dementia with Lewy Bodies (DLB). Researchers planned to give 45 participants either a low dose, high dose, or placebo for 12 weeks, then check for side effects and measure changes in brain and blood markers. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Skin, speech, and brain scans may unmask hidden neurodegeneration
- Can sound waves soothe Dementia's emotional turmoil?
- Cancer drug shows promise for treating lewy body dementia
- Could tiny doses of radiation slow Alzheimer's? a new trial investigates
- Brain scans track Alzheimer's clues over decades
- Can a One-Time bone drug shield Parkinson's patients from fractures?